MK-3697

A detailed overview of the investigational drug MK-3697

CaptionSynonyms

MK-3697

Drug Information
Image
Identifiers CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL		Chemical Data C H N O Molecular Weight

MK-3697 is an investigational drug developed by Merck & Co. for the treatment of various neurological and psychiatric disorders. It is primarily being studied for its potential use in treating major depressive disorder (MDD) and anxiety disorders.

Mechanism of Action

MK-3697 is believed to function as a selective agonist of the serotonin receptor subtype 5-HT_1A. This receptor is a subtype of the 5-HT receptor family, which is a group of G protein-coupled receptors that mediate the effects of the neurotransmitter serotonin. By selectively targeting the 5-HT_1A receptor, MK-3697 may help modulate mood and anxiety levels, potentially offering therapeutic benefits for patients with mood disorders.

Pharmacokinetics

The pharmacokinetic profile of MK-3697 includes its absorption, distribution, metabolism, and excretion (ADME) characteristics. Studies have shown that MK-3697 is well-absorbed when administered orally, with a bioavailability that supports its use as an oral medication. The drug is metabolized primarily in the liver, and its metabolites are excreted via the kidneys.

Clinical Trials

MK-3697 has undergone several phases of clinical trials to evaluate its safety and efficacy. In early-phase trials, the drug demonstrated a favorable safety profile with mild to moderate side effects. Subsequent trials focused on its efficacy in treating symptoms of major depressive disorder and anxiety. Results from these trials have shown promise, with significant improvements in mood and anxiety scores compared to placebo.

Potential Side Effects

As with many drugs targeting the central nervous system, MK-3697 may cause side effects. Commonly reported side effects include nausea, dizziness, and headache. More serious side effects are rare but may include changes in mood or behavior, which should be monitored closely by healthcare providers.

Regulatory Status

As of the latest updates, MK-3697 is still in the investigational stage and has not yet received approval from major regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Ongoing studies aim to further elucidate its safety and efficacy profile to support future regulatory submissions.

Also see

• Serotonin receptor agonists
• Major depressive disorder
• Anxiety disorders
• G protein-coupled receptors